# US Autoimmune Disease Diagnostics Market

> US Autoimmune Disease Diagnostics Market Research Report: Size, Share, Trend Analysis By Test Type (Serological Tests, Molecular Diagnostics, Imaging Tests, Biopsies), By Disease Type (Rheumatoid Arthritis, Lupus, Multiple Sclerosis, Type 1 Diabetes, Thyroid Disorders), By End Users (Hospitals, Diagnostic Laboratories, Research Institutes) and By Product Type (Reagents, Instrumentations, Software) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.72%
- **2024:** $ 1,272.58 Million
- **2025:** $ 1,358.1 Million
- **2035:** $ 2,602.62 Million
- **Key Players:** Abbott Laboratories (US), Roche Holding AG (CH), Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (DE), Bristol-Myers Squibb Company (US), Quest Diagnostics Incorporated (US), Bio-Rad Laboratories Inc. (US), Genzyme Corporation (US)

**Report ID:** MRFR/LS/14149-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-autoimmune-disease-diagnostics-market-15676

---

## Market Summary

## **US Autoimmune Disease Diagnostics Market Overview**

As per MRFR analysis, the US Autoimmune Disease Diagnostics Market Size was estimated at 1.56 (USD Billion) in 2023. The US Autoimmune Disease Diagnostics Market Industry is expected to grow from 1.75(USD Billion) in 2024 to 3.5 (USD Billion) by 2035. The US Autoimmune Disease Diagnostics Market CAGR (growth rate) is expected to be around 6.504% during the forecast period (2025 - 2035).

### **Key US Autoimmune Disease Diagnostics Market Trends Highlighted**

The US Autoimmune Disease Diagnostics Market is experiencing several notable trends driven by a combination of technological advancements and increasing awareness of autoimmune diseases. One significant market driver is the rise in the prevalence of autoimmune conditions in the United States, with reports indicating that approximately 50 million Americans are affected by some form of autoimmune disorder. This growing patient population fuels the demand for accurate and efficient diagnostic tools. Additionally, the increased focus on personalized medicine and tailored treatment approaches encourages the development of innovative diagnostic solutions that can identify specific autoantibodies, contributing to better patient outcomes.

Opportunities in the market are expanding with the ongoing advancements in laboratory techniques, such as enzyme-linked immunosorbent assays (ELISA) and multiplex testing, which enhance the accuracy and speed of autoimmune disease diagnosis. Furthermore, there is a rising interest in point-of-care testing technologies that facilitate rapid diagnosis at home or remote settings, providing convenience for patients and healthcare providers. This trend is particularly significant in rural areas of the US, where access to specialized healthcare services may be limited.

Recent times have seen an increase in collaborations between diagnostic companies, academic institutions, and healthcare providers to advance research and develop innovative diagnostic tools.

There is also a shift towards incorporating artificial intelligence and machine learning in the analysis of diagnostic data, promising greater precision and quicker results. The overall landscape of the US Autoimmune Disease Diagnostics Market is evolving, reflecting a growing commitment to improving diagnostic accuracy and patient care for autoimmune diseases.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Autoimmune Disease Diagnostics Market Drivers**

### **Increasing Prevalence of Autoimmune Diseases**

The US Autoimmune Disease Diagnostics Market Industry is significantly driven by the rising incidence of autoimmune diseases, which are currently affecting approximately 24 million people in the United States according to the National Institute of Health (NIH). The increasing number of diagnosed cases creates a higher demand for effective diagnostic tests. It has been reported that autoimmune diseases have seen a rise of around 19% over the last decade, indicating that more individuals are recognizing and being diagnosed with these conditions.

This trend is expected to continue as awareness increases and diagnostic technologies improve. Established organizations like the American Autoimmune Related Diseases Association (AARDA) highlight the growing awareness, leading to more patients seeking diagnostic services. The increasing prevalence directly correlates to the market growth since more patients means greater demand for diagnostic services and products tailored specifically for these diseases.

### **Technological Advancements in Diagnostic Tools**

Technological innovation in the US Autoimmune Disease Diagnostics Market Industry is another prominent driver contributing to market growth. Advancements in laboratory equipment and testing methods, including the introduction of next-generation sequencing and multiplex immunoassays, have made it easier and faster to diagnose complex autoimmune diseases. As a result, the accuracy and reliability of diagnostic results have improved. According to the FDA, numerous new diagnostic tests have been approved in recent years, significantly increasing the number of available options on the market.

Companies like Abbott Laboratories and Thermo Fisher Scientific are pivotal in bringing these innovations to the market, influencing the diagnostics landscape and improving test accessibility and efficiency.

### **Growing Investment in Research and Development**

Investment in Research and Development (R&D) for autoimmune diseases is steadily increasing, which acts as a critical driver in the US Autoimmune Disease Diagnostics Market Industry. Recent reports indicate that the National Institutes of Health is investing over 2.5 billion USD annually in autoimmune disease research, bolstering innovation in diagnostic methods. This funding supports not only the development of new diagnostic tests but also enhances our understanding of autoimmune diseases, thereby creating a higher demand for innovative diagnostics.

Leading biotechnology companies are also allocating substantial resources towards R&D, paving the way for breakthroughs in the identification of these chronic diseases, thus contributing to the market's growth and ensuring more accurate and timely diagnoses for patients.

## **US Autoimmune Disease Diagnostics Market Segment Insights**

### **Autoimmune Disease Diagnostics Market Test Type Insights**

The US Autoimmune Disease Diagnostics Market is primarily structured around various test types that cater to the diagnostics of autoimmune diseases, crucially impacting patient management and treatment pathways. Within this segment, Serological Tests are among the most widely utilized and are essential for detecting specific antibodies associated with various autoimmune disorders. The demand for such tests is driven by the increasing prevalence of autoimmune diseases, which have shown a notable surge in recent years, underscoring the necessity for accurate and timely diagnosis.

Moreover, Molecular Diagnostics play a significant role in the market, offering precise identification of genetic disorders and providing insights into disease mechanisms.

These tests have gained traction due to advancements in technology and the need for personalized medicine, enabling healthcare professionals to tailor treatment plans according to individual patient profiles. The reliability and accuracy of Molecular Diagnostics followed by the emerging trends in genomics are attracting significant investments, further enhancing their importance in autoimmune disease management. Additionally, Imaging Tests contribute notably to the diagnostic landscape by allowing physicians to visualize affected areas within the body. These tests provide real-time insight into disease progression and the effectiveness of treatments, making them invaluable in managing complex autoimmune conditions.

Their integration with and support of other diagnostic methods enhances overall patient assessments and outcomes. Biopsies are also a critical component of the test type spectrum, serving as a definitive method for diagnosing specific autoimmune disorders. By obtaining tissue samples for examination, Biopsies facilitate accurate diagnoses, which significantly informs clinical decision-making regarding treatment strategies. The reliance on Biopsies is indicative of their importance in conjunction with other diagnostic techniques, offering a comprehensive approach to understanding autoimmune diseases.

Overall, the Test Type segmentation within the US Autoimmune Disease Diagnostics Market is characterized by a blend of traditional and advanced methodologies, each contributing uniquely to the growing need for effective diagnostics in the realm of autoimmune disorders. As the awareness of such diseases rises, along with advancements in technology, the Test Type segment is poised for continuous evolution, addressing the complex and diverse needs of patients effectively.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Autoimmune Disease Diagnostics Market Disease Type Insights**

The US Autoimmune Disease Diagnostics Market, with a notable focus on the Disease Type segment, encompasses a variety of critical conditions that shape the industry's dynamics. Among these, Rheumatoid Arthritis takes a significant share, often leading to extensive healthcare costs and impacting the quality of life for many patients. Lupus remains challenging due to its complex diagnostic criteria, thus driving demand for innovative diagnostic solutions. Multiple Sclerosis is also pivotal, as advancements in imaging and testing methods contribute substantially to early diagnosis and management, which is crucial for patient outcomes.

Additionally, Type 1 Diabetes highlights the growing need for effective monitoring tools, reflecting an increasing awareness of autoimmune-related complications. Meanwhile, Thyroid Disorders represent another key area, influenced by substantial awareness campaigns and the rising incidence of thyroid abnormalities in the population. This segment of the US Autoimmune Disease Diagnostics Market demonstrates robust growth potential, underscored by rising healthcare expenditures, advancements in technology, and increased prevalence of autoimmune diseases, thereby offering numerous opportunities to stakeholders within the industry.

### **Autoimmune Disease Diagnostics Market End User Insights**

The US Autoimmune Disease Diagnostics Market has diverse end users, primarily encompassing Hospitals, Diagnostic Laboratories, and Research Institutes, each playing a vital role in disease management and diagnosis. Hospitals serve as critical hubs for patient diagnosis and treatment, equipped with advanced diagnostic tools to facilitate timely detection of autoimmune diseases. Meanwhile, Diagnostic Laboratories, often associated with hospitals or operating independently, dominate a significant share of testing services, providing precise and reliable results that are essential for effective patient care.

Research Institutes contribute by innovating and advancing diagnostic methodologies, enhancing the overall landscape of autoimmune disease understanding through specialized studies and trials. The increasing incidence of autoimmune disorders in the US is driving demand across all these end users, complemented by a greater push for early diagnostics, personalized treatment options, and improved patient outcomes. The complexity of autoimmune diseases necessitates the collaboration of these segments, offering exceptional opportunities for enhanced diagnostic solutions and fostering significant growth in the US Autoimmune Disease Diagnostics Market, with data indicating a steady upward trend in investments and innovations in diagnostic technologies.

### **Autoimmune Disease Diagnostics Market Product Type Insights**

The US Autoimmune Disease Diagnostics Market is prominently segmented into Product Types, focusing on Reagents, Instrumentation, and Software. Reagents are essential as they serve as the key consumables that facilitate testing and detection in autoimmune diagnostics. This segment holds a significant share in the market, driven by the increasing prevalence of autoimmune disorders across the United States. Instrumentation is also crucial, providing the necessary equipment for accurate diagnostics, and embodying technological advancements that enhance the efficiency and reliability of tests.

Moreover, the Software segment is gaining traction, as it plays a vital role in data management and analysis, streamlining laboratory operations, and ensuring compliance with regulatory standards. As the demand for innovative diagnostic solutions grows, driven by rising healthcare expenditures and advancements in technology, the significance of these Product Types continues to escalate. Market trends indicate a shift toward more automated and integrated diagnostic systems, highlighting the role of these segments in driving improvements in patient outcomes and operational efficiency within healthcare systems throughout the US.

Overall, the US Autoimmune Disease Diagnostics Market demonstrates a clear trajectory of growth and innovation within these key segments, reflecting the ongoing commitment to improving diagnostic capabilities and patient care.

## **US Autoimmune Disease Diagnostics Market Key Players and Competitive Insights**

The US Autoimmune Disease Diagnostics Market is characterized by a dynamic competitive landscape, with a variety of key players driving innovation and growth within the sector. As autoimmune diseases continue to rise in prevalence, the demand for accurate and efficient diagnostic tools has intensified, prompting companies to invest in advanced technologies and novel testing methodologies. In this market, organizations are focusing on enhancing their product portfolios and expanding their geographical reach to capture a larger share.

The competitive environment is not only shaped by the introduction of new diagnostic tests but also by strategic collaborations, partnerships, and mergers aimed at bolstering research and development capabilities while addressing varying patient needs across the region.

Danaher Corporation holds a significant presence in the US Autoimmune Disease Diagnostics Market, leveraging its extensive portfolio of diagnostic products and technologies. The company is recognized for its innovative diagnostic platforms, which enhance the accuracy and speed of autoimmune disease detection, achieving high sensitivity and specificity for various conditions. Danaher’s strengths lie in its robust R&D capabilities, which allow for the continuous development of cutting-edge diagnostic solutions that cater to evolving market demands. Furthermore, the company benefits from a strong distribution network and established relationships with healthcare providers, enabling it to effectively reach its target audience.

Its commitment to enhancing patient outcomes through high-quality products solidifies its position as a leading player in the autoimmune diagnostics sector.

Genentech operates prominently in the US Autoimmune Disease Diagnostics Market, with a strong emphasis on developing targeted therapies and diagnostic solutions that address specific autoimmune conditions. The company's robust drug development pipeline includes innovative therapies that are grounded in extensive research and clinical studies. Genentech's strengths include its pioneering role in precision medicine, coupled with significant investments in advanced research to create comprehensive diagnostic tests that can aid in disease management and treatment decision-making. The company frequently engages in strategic partnerships and collaborations with other organizations to enhance its research capabilities, driving innovation in both diagnostics and therapeutics.

Moreover, Genentech’s strong brand reputation and commitment to improving patient care through effective diagnostics further solidify its position within the US market landscape.

### **Key Companies in the US Autoimmune Disease Diagnostics Market Include**

## **US Autoimmune Disease Diagnostics Market Industry Developments**

Recent developments in the US Autoimmune Disease Diagnostics Market have seen significant activity, particularly among major players such as Danaher Corporation, Genentech, Novartis, Roche Diagnostics, Merck and Co., Bristol Myers Squibb, Abbott Laboratories, Eli Lilly and Company, F. Hoffmann La Roche, Thermo Fisher Scientific, Siemens Healthineers, Quest Diagnostics, Biogen, and Labcorp. The market is experiencing notable growth driven by advancements in diagnostic technologies, such as biomarker identification and automated testing systems, which enhance diagnostic accuracy and patient outcomes. In terms of mergers and acquisitions, recent activities include Abbott Laboratories announcing its acquisition of St.

Jude Medical in January 2017, focusing on expanding its diagnostic capabilities, and Roche Diagnostics acquiring TIB Molbiol in December 2020 to enhance its molecular diagnostics portfolio.

Moreover, the market continues to evolve with regulatory changes, reflecting efforts to improve access to innovative diagnostic tests. From a financial perspective, this sector is anticipated to grow significantly due to increasing autoimmune disease prevalence and rising healthcare investments, which further bolsters the diagnostic development landscape. Overall, the US Autoimmune Disease Diagnostics Market remains a dynamic field with ongoing advancements and strategic collaborations among key industry players.

## **US Autoimmune Disease Diagnostics Market Segmentation Insights**

### **Autoimmune Disease Diagnostics Market Test Type Outlook**

### **Autoimmune Disease Diagnostics Market Disease Type Outlook**

### **Autoimmune Disease Diagnostics Market End User Outlook**

### **Autoimmune Disease Diagnostics Market Product Type Outlook**

## Market Drivers

### Advancements in Biomarker Discovery

The autoimmune disease-diagnostics market is significantly influenced by advancements in biomarker discovery. The identification of specific biomarkers associated with various autoimmune diseases enhances diagnostic accuracy and enables personalized treatment approaches. Recent studies have shown that utilizing biomarkers can improve diagnostic sensitivity by up to 30%, which is crucial for early intervention. As research institutions and biotechnology companies invest in biomarker research, the market is likely to witness a surge in novel diagnostic tests. This trend not only supports the development of targeted therapies but also aligns with the growing emphasis on precision medicine in the healthcare landscape.

### Rising Consumer Awareness and Education

The autoimmune disease-diagnostics market is positively impacted by rising consumer awareness and education regarding autoimmune disorders. As patients become more informed about their health, they are more likely to seek diagnostic testing for potential autoimmune conditions. Educational campaigns and advocacy groups play a crucial role in disseminating information, leading to increased testing rates. Surveys indicate that 60% of individuals are now aware of the symptoms associated with autoimmune diseases, prompting them to consult healthcare professionals. This heightened awareness is expected to drive demand for diagnostic services, thereby contributing to the growth of the autoimmune disease-diagnostics market.

### Growing Demand for Point-of-Care Testing

The autoimmune disease-diagnostics market is witnessing a shift towards point-of-care testing (POCT), driven by the need for rapid and convenient diagnostic solutions. Patients and healthcare providers increasingly prefer tests that can be conducted at the point of care, reducing the time between diagnosis and treatment initiation. The market for POCT in autoimmune diseases is projected to grow at a CAGR of 15% over the next five years. This trend reflects a broader movement towards decentralized healthcare, where accessibility and efficiency are prioritized. Consequently, the demand for innovative POCT solutions is likely to shape the future of the autoimmune disease-diagnostics market.

### Rising Prevalence of Autoimmune Disorders

The autoimmune disease-diagnostics market is experiencing growth due to the increasing prevalence of autoimmune disorders in the US. Conditions such as rheumatoid arthritis, lupus, and multiple sclerosis are becoming more common, affecting millions of individuals. According to the National Institutes of Health, approximately 24 million Americans are currently diagnosed with autoimmune diseases. This rising incidence necessitates advanced diagnostic tools to ensure timely and accurate detection, thereby driving demand within the autoimmune disease-diagnostics market. As healthcare providers seek to improve patient outcomes, the need for innovative diagnostic solutions becomes paramount, indicating a robust market potential.

### Increased Investment in Healthcare Infrastructure

The autoimmune disease-diagnostics market benefits from increased investment in healthcare infrastructure across the US. Government initiatives and private sector funding are directed towards enhancing laboratory capabilities and expanding access to diagnostic services. For instance, the US government allocated approximately $2 billion in 2025 to improve diagnostic facilities and promote research in autoimmune diseases. This financial support fosters innovation and encourages the development of advanced diagnostic technologies. As healthcare systems evolve, the availability of state-of-the-art diagnostic tools is expected to rise, further propelling the growth of the autoimmune disease-diagnostics market.

## Future Outlook

The [Autoimmune Disease Diagnostics Market](https://www.marketresearchfuture.com/reports/autoimmune-disease-diagnostics-market-6715) is projected to grow at a 6.72% CAGR from 2025 to 2035, driven by technological advancements and increasing disease prevalence.

**New opportunities:**

- Development of AI-driven diagnostic tools for early detection Expansion of telehealth services for remote patient monitoring Partnerships with biotech firms for innovative biomarker discovery

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

## Segment Insights

### By Test Type: Serological Tests (Largest) vs. Molecular Diagnostics (Fastest-Growing)

In the US autoimmune disease-diagnostics market, serological tests dominate the landscape, holding a substantial market share due to their widespread usage and effectiveness in detecting specific autoantibodies. This segment is integral for initial screenings and is often the first line of testing for autoimmune conditions. On the other hand, molecular diagnostics are rapidly gaining traction, leveraging advanced genetic and molecular techniques for a more precise diagnosis, albeit from a smaller share of the market. Growth trends indicate a significant rise in the demand for molecular diagnostics, driven by technological advancements and the increasing need for accurate, rapid testing methods. As the healthcare landscape evolves, a shift towards [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937) fuels the adoption of these innovative tests. Additionally, the aging population and heightened awareness about autoimmune diseases contribute to market expansion for both segment values, highlighting the vital role they play in this critical healthcare area.

Serological Tests (Dominant) vs. Molecular Diagnostics (Emerging)

Serological tests are a cornerstone of the diagnostic process in autoimmune diseases, offering reliable and swift results for clinicians. They are characterized by their ability to detect a variety of autoimmune disorders through the identification of specific autoantibodies in the serum. This segment's dominance is attributed to its established methodologies and widespread acceptance in clinical practices. On the contrary, molecular diagnostics represent an emerging field that focuses on genetic testing and biomarkers, providing a more nuanced understanding of autoimmune conditions. As this technology becomes more accessible and affordable, it is expected to redefine the diagnostic landscape by offering more precise and individualized treatment options, positioning it as a significant player in the future of the US autoimmune disease-diagnostics market.

### By Disease Type: Rheumatoid Arthritis (Largest) vs. Lupus (Fastest-Growing)

In the US autoimmune disease-diagnostics market, Rheumatoid Arthritis holds the largest market share among the various disease types. This segment is significantly driven by the high prevalence of the condition and increased awareness of diagnostic tools available. Following closely is Lupus, which, while having a smaller market share, is quickly gaining traction as more innovative diagnostic methods are being developed and adopted for early detection. Growth trends within this segment are fueled by advancements in technology and an increasing focus on personalized medicine. Rising investments in research and development are also contributing to the enhancement of diagnostic capabilities for these autoimmune diseases. Additionally, the expanding prevalence of autoimmune disorders highlighting the importance of early diagnosis has spurred demand for efficient diagnostic solutions.

Rheumatoid Arthritis (Dominant) vs. Lupus (Emerging)

Rheumatoid Arthritis is the dominant force in the US autoimmune disease-diagnostics market, characterized by its widespread recognition and comprehensive diagnostic methodologies available. The segment benefits from a well-established framework of diagnostic processes, ensuring accurate detection and management of the disease. In contrast, Lupus, categorized as an emerging segment, is experiencing rapid growth due to innovative diagnostic tools aimed at improving detection rates. This segment is seeing a rise in collaborations between diagnostic companies and healthcare providers to enhance awareness and treatments. As such, Lupus is becoming an increasingly vital area of focus, promising to shape the future landscape of diagnostics in autoimmune diseases.

### By End-user: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the US autoimmune disease-diagnostics market, hospitals are the largest end-user segment, capturing a significant share due to their ability to provide comprehensive care and diagnostic services. Diagnostic laboratories follow closely, displaying a robust growth trajectory as they expand their capabilities and services in diagnostics related to autoimmune diseases. Research institutes, while important, represent a smaller portion of the market, primarily focused on clinical research and advancements in diagnostic technologies. Growth trends for the US autoimmune disease-diagnostics market are driven by increasing autoimmune disorder prevalence and advancements in diagnostic technologies. Hospitals are optimizing their operations to accommodate more patients, while diagnostic laboratories are investing in cutting-edge technologies to enhance accuracy and speed of results. The research institutes play a crucial role in innovation, pushing forward diagnostics to address unmet medical needs in autoimmune diseases through dedicated studies and clinical trials.

Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals remain the dominant end-user in the US autoimmune disease-diagnostics market, primarily due to their extensive resources, integrated care approach, and ability to access diagnostic tools. They are equipped with advanced labs and skilled personnel, enabling them to handle a high volume of tests efficiently. On the other hand, diagnostic laboratories are emerging as key players, increasingly being recognized for their specialized services and quicker turnaround times. This segment is expanding through collaborations with hospitals and healthcare practitioners, focusing on tailored diagnostic solutions for autoimmune diseases, thus bridging gaps in hospital capabilities. Overall, these contrasting roles highlight the interdependence and evolving landscape within the diagnostic ecosystem.

### By Product Type: Reagents (Largest) vs. Instrumentations (Fastest-Growing)

In the US autoimmune disease-diagnostics market, the market share is primarily dominated by reagents, which play a critical role in numerous diagnostic tests. Instrumentations follow closely, indicating significant relevance for the overall diagnostic processes. Software solutions, while essential for data management, hold a smaller share compared to the physical components like reagents and instrumentations. The robust performance of reagents can be attributed to their widespread use in various diagnostic settings, further emphasizing their dominant status. Growth trends reveal that the instrumentation segment is the fastest-growing area within the segment, fueled by technological advancements and increased automation in diagnostic processes. The enhancing capabilities of software solutions also contribute to the market, facilitating improved data analytics and management in diagnostics. As healthcare providers seek more efficient and accurate testing methodologies, the demand for innovative instrumentation continues to rise, offering substantial growth potential going forward.

Reagents (Dominant) vs. Instrumentations (Emerging)

Reagents are the dominant force in the US autoimmune disease-diagnostics market, characterized by their essential role in conducting various diagnostic tests, which are crucial in detecting autoimmune diseases. They are highly versatile, used in a range of applications from laboratory settings to point-of-care testing. Instrumentations, while emerging, are gaining traction due to their technological advancements, with many new devices entering the market that enhance testing precision and efficiency. This segment is experiencing growing traction, largely driven by the demand for automation and efficiency in diagnostic processes. Both segment values provide unique advantages, but reagents remain at the forefront of diagnostic practices, while instrumentations show significant promise for future growth.

## Competitive Benchmarking

The autoimmune disease-diagnostics market is characterized by a dynamic competitive landscape, driven by increasing prevalence of autoimmune disorders and advancements in diagnostic technologies. Key players such as Abbott Laboratories (US), Roche Holding AG (CH), and Thermo Fisher Scientific Inc. (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Abbott Laboratories (US) focuses on innovation through the development of novel diagnostic tests, while Roche Holding AG (CH) emphasizes strategic partnerships to expand its product offerings. Thermo Fisher Scientific Inc. (US) is leveraging [digital transformation](https://www.marketresearchfuture.com/reports/digital-transformation-market-8685) to optimize its operations and improve customer engagement, collectively shaping a competitive environment that prioritizes technological advancement and strategic collaboration. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with several key players exerting substantial influence. This fragmentation allows for a diverse range of diagnostic solutions, catering to various segments within the autoimmune disease-diagnostics market. In October 2025, Abbott Laboratories (US) announced the launch of a new autoimmune diagnostic test that utilizes advanced biomarker technology, potentially revolutionizing early detection methods. This strategic move is significant as it not only enhances Abbott's product portfolio but also positions the company as a leader in innovative diagnostic solutions, likely attracting a broader customer base. In September 2025, Roche Holding AG (CH) entered into a collaboration with a leading biotechnology firm to develop next-generation diagnostic tools for autoimmune diseases. This partnership is indicative of Roche's commitment to expanding its capabilities and underscores the importance of collaboration in driving innovation within the market. Such alliances may enhance Roche's competitive edge by integrating cutting-edge technologies into its diagnostic offerings. In August 2025, Thermo Fisher Scientific Inc. (US) unveiled a new digital platform aimed at streamlining laboratory workflows and improving data management for autoimmune diagnostics. This initiative reflects the growing trend towards digitalization in the healthcare sector, suggesting that Thermo Fisher is positioning itself to meet the evolving needs of laboratories and healthcare providers. As of November 2025, current competitive trends in the autoimmune disease-diagnostics market include a pronounced focus on digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a model that emphasizes innovation, technological advancement, and supply chain reliability, thereby enhancing overall market resilience.

## Recent News & Developments

Recent developments in the US Autoimmune Disease Diagnostics Market have seen significant activity, particularly among major players such as Danaher Corporation, Genentech, Novartis, Roche Diagnostics, Merck and Co., Bristol Myers Squibb, Abbott Laboratories, Eli Lilly and Company, F. Hoffmann La Roche, Thermo Fisher Scientific, Siemens Healthineers, Quest Diagnostics, Biogen, and Labcorp. The market is experiencing notable growth driven by advancements in diagnostic technologies, such as biomarker identification and automated testing systems, which enhance diagnostic accuracy and patient outcomes. In terms of mergers and acquisitions, recent activities include Abbott Laboratories announcing its acquisition of St.

Jude Medical in January 2017, focusing on expanding its diagnostic capabilities, and Roche Diagnostics acquiring TIB Molbiol in December 2020 to enhance its molecular diagnostics portfolio.

Moreover, the market continues to evolve with regulatory changes, reflecting efforts to improve access to innovative diagnostic tests. From a financial perspective, this sector is anticipated to grow significantly due to increasing autoimmune disease prevalence and rising healthcare investments, which further bolsters the diagnostic development landscape. Overall, the US Autoimmune Disease Diagnostics Market remains a dynamic field with ongoing advancements and strategic collaborations among key industry players.

## Report Scope

| MARKET SIZE 2024 | 1272.58(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1358.1(USD Million) |
| MARKET SIZE 2035 | 2602.62(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.72% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Abbott Laboratories (US), Roche Holding AG (CH), Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (DE), Bristol-Myers Squibb Company (US), Quest Diagnostics Incorporated (US), Bio-Rad Laboratories Inc. (US), Genzyme Corporation (US) |
| Segments Covered | Test Type, Disease Type, End-user, Product Type |
| Key Market Opportunities | Integration of advanced biomarker technologies enhances diagnostic accuracy in the autoimmune disease-diagnostics market. |
| Key Market Dynamics | Technological advancements drive innovation in autoimmune disease diagnostics, enhancing accuracy and efficiency in testing. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US autoimmune disease-diagnostics market in 2024?**
A: The market valuation was $1272.58 Million in 2024.

**Q: What is the projected market valuation for the US autoimmune disease-diagnostics market by 2035?**
A: The projected valuation for 2035 is $2602.62 Million.

**Q: What is the expected CAGR for the US autoimmune disease-diagnostics market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.72% during the forecast period 2025 - 2035.

**Q: Which test type segment had the highest valuation in 2024?**
A: Molecular Diagnostics had the highest valuation at $400.0 Million in 2024.

**Q: What is the projected valuation for the Biopsies segment by 2035?**
A: The projected valuation for the Biopsies segment is $702.62 Million by 2035.

**Q: Which disease type segment is expected to show significant growth by 2035?**
A: Thyroid Disorders is expected to show significant growth, with a projected valuation of $802.62 Million by 2035.

**Q: What was the valuation of the Diagnostic Laboratories segment in 2024?**
A: The valuation of the Diagnostic Laboratories segment was $600.0 Million in 2024.

**Q: Which product type segment is anticipated to have the highest growth by 2035?**
A: Reagents are anticipated to have the highest growth, with a projected valuation of $1200.0 Million by 2035.

**Q: Who are the key players in the US autoimmune disease-diagnostics market?**
A: Key players include Abbott Laboratories, Roche Holding AG, and Thermo Fisher Scientific Inc.

**Q: What was the valuation of the Multiple Sclerosis segment in 2024?**
A: The valuation of the Multiple Sclerosis segment was $250.0 Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-autoimmune-disease-diagnostics-market-15676*